Emergent Biosolutions, Inc. (NYSE:EBS) Chairman Fuad El-Hibri sold 16,439 shares of Emergent Biosolutions stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $37.50, for a total value of $616,462.50. Following the completion of the sale, the chairman now owns 1,605,216 shares of the company’s stock, valued at $60,195,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Fuad El-Hibri also recently made the following trade(s):

  • On Tuesday, September 5th, Fuad El-Hibri sold 3,100 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total value of $116,250.00.
  • On Thursday, August 31st, Fuad El-Hibri sold 5,461 shares of Emergent Biosolutions stock. The stock was sold at an average price of $37.50, for a total value of $204,787.50.
  • On Thursday, July 27th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $36.50, for a total value of $912,500.00.
  • On Thursday, July 20th, Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $35.50, for a total value of $887,500.00.

Shares of Emergent Biosolutions, Inc. (EBS) opened at 37.64 on Monday. Emergent Biosolutions, Inc. has a 12-month low of $24.47 and a 12-month high of $37.98. The company has a market cap of $1.55 billion, a P/E ratio of 23.97 and a beta of 1.23. The stock’s 50 day moving average price is $35.89 and its 200 day moving average price is $32.31.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.26 by $0.13. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The company had revenue of $100.77 million for the quarter, compared to the consensus estimate of $111.57 million. During the same period last year, the business earned ($0.05) EPS. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. On average, analysts forecast that Emergent Biosolutions, Inc. will post $1.54 EPS for the current year.

WARNING: “Emergent Biosolutions, Inc. (EBS) Chairman Sells $616,462.50 in Stock” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/11/emergent-biosolutions-inc-ebs-chairman-sells-616462-50-in-stock.html.

A number of hedge funds have recently bought and sold shares of EBS. Riverhead Capital Management LLC increased its position in Emergent Biosolutions by 102.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in Emergent Biosolutions by 23.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 587 shares in the last quarter. State of Alaska Department of Revenue increased its position in Emergent Biosolutions by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 100 shares in the last quarter. Creative Planning increased its position in Emergent Biosolutions by 1.2% during the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 55 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Emergent Biosolutions by 17.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 844 shares in the last quarter. 85.44% of the stock is owned by institutional investors.

A number of equities research analysts have weighed in on EBS shares. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a report on Friday, August 25th. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $44.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.